Primary Biliary Cholangitis (PBC) Clinical Trial
Official title:
Safety and Efficacy of Probiotics in Primary Biliary Cholangitis (PBC) Patients With Poor Ursodeoxycholic Acid (UDCA) Response
The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor ursodeoxycholic acid (UDCA) response.
PBC patients with poor ursodeoxycholic acid (UDCA) response are selected and randomly assigned into probiotic group and control group. Patients in probiotic group receive probiotic(Micro V Probiotics) combined UDCA for 6 months and then continue to take UDCA alone. Patients in control group continue to take UDCA alone. Biochemical indicators, immunological indicators, liver stiffness, and ultrasound of the two groups of patients were collected. GLOBE and UK-PBC scoring system are used to assesse prognosis.The feces and serum of all patients are collected to observe the differences in fecal microbial polymorphisms in the two groups of patients. Metabolomics are used to study the differences in the bile acids and short chain fatty acid metabolites of the serum and feces of the two groups of PBC patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03188146 -
Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
|
||
| Recruiting |
NCT05896124 -
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
|
Phase 2 | |
| Recruiting |
NCT06016842 -
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
|
Phase 3 | |
| Completed |
NCT04047160 -
Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)
|
Phase 1 | |
| Completed |
NCT03124108 -
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
|
Phase 2 |